Using AI to find biomarkers for better treatment of pancreatic cancer
Official title: A Retrospective/Prospective Study of an Artificial Intelligence Derived Histological Biomarker to Select Neoadjuvant Treatment for Patients With Borderline Resectable or Resectable Pancreatic Ductal Adenocarcinoma
Run by Roswell Park Cancer Institute · NCT06320717 · Data updated 2026-11-12
This study is trying to find specific markers in blood and tumor samples from pancreatic cancer patients to see if they can help doctors choose the best treatments for future patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Roswell Park Cancer Institute Academic / other |
| Locations | 2 sites (Buffalo, New York and 1 other locations) |
| Status | Recruiting |
| Started | January 2, 2024 |
| Main results expected | December 2, 2026 |
| Study ends | December 2, 2026 |
| Registry record updated | July 23, 2026 |
| Trial ID | NCT06320717 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with borderline resectable pancreatic ductal adenocarcinoma who have not received prior systemic treatment.
✕Probably not a fit
Patients with concurrent malignancies requiring active treatment or those who have previously undergone systemic treatment for pancreatic cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to collect blood samples and tumor tissue from patients with borderline resectable pancreatic ductal adenocarcinoma who are undergoing standard neoadjuvant treatments like FOLFIRINOX or Gemcitabine combined with Nab-paclitaxel. The goal is to identify potential biomarkers that correlate with treatment responses, which could help in selecting the most effective treatment options for future patients. By analyzing these samples, researchers hope to enhance personalized treatment strategies for this challenging cancer type.
Why it matters
Potential benefit: If successful, this approach could lead to more tailored and effective treatment options for patients with pancreatic cancer.
How similar studies have gone: While the use of biomarkers in cancer treatment is a growing field, this specific approach utilizing AI to select neoadjuvant treatments for pancreatic cancer is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have histologically or cytologically confirmed PDAC that is borderline resectable (BR) (Cohort A) OR have histologically or cytologically confirmed PDAC that is resectable (Cohort B) using the National Comprehensive Cancer Network criteria \[35\]. * Availability of archival tumor tissue (diagnostic for PDAC) required * Have a documented ECOG Performance Status of ≤ 1 * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form (ICF) prior to receiving any study related procedure. Exclusion Criteria: * Has received prior systemic treatment (standard of care or experimental) for PDAC * Participant has a concurrent malignancy requiring active treatment during the study.
Where it's running
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States Recruiting -
Good Samaritan University Hospital
West Islip, New York, United States Recruiting
Study contacts
- Principal investigator: Christos Fountilas, MD — Roswell Park Comprehensive Cancer Center
- Study coordinator: Christos Fountzilas, MD
- Email: Christos.Fountzilas@roswellpark.org
- Phone: 716-845-2300
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery
This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
-
Telisotuzumab Adizutecan with Gemcitabine and Nab-Paclitaxel in Pancreatobiliary Cancers
This study tests whether adding telisotuzumab adizutecan to standard chemotherapy can help adults with pancreatobiliary cancers see a benefit.
-
GFH276 with Cetuximab or chemotherapy in RAS-mutated solid tumors and PDAC
This study tests whether GFH276 combined with cetuximab or standard chemotherapy can help adults with advanced solid tumors or pancreatic cancer that carry a RAS mutation.
-
First-in-human test of BLU-924 for KRAS-mutant advanced cancers
This trial tests BLU-924 in adults with KRAS-mutant advanced solid tumors, including PDAC, NSCLC, and CRC, to see if it is safe and may help control cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.